Michelle Mojadidi
AstraZeneca (Brazil)(BR)AstraZeneca (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, CRISPR and Genetic Engineering, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune Cell Function and Interaction
Most-Cited Works
- → CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells(2016)214 cited
- → Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases(2016)56 cited
- → A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.(2017)32 cited
- → Bioluminescence Imaging of Angiogenesis in a Murine Orthotopic Pancreatic Cancer Model(2010)20 cited
- → Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)(2017)12 cited
- → 198 Costimulatory antigen receptor (CoStAR): a novel platform that enhances the activity of tumor infiltrating lymphocytes (TILs)(2021)4 cited
- → Antitumor activity of T cells expressing a novel anti-folate receptor alpha (FOLR1) costimulatory antigen receptor (CoStAR) in a human xenograft murine solid tumor model and implications for in-human studies.(2022)4 cited
- → Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.(2024)2 cited
- → 282 Anti-folate receptor alpha (FRα) costimulatory antigen receptor (CoStAR) improves T-cell function across physiologically relevant ranges of FRα expression and T-cell receptor (TCR) affinities(2022)1 cited
- → Non-clinical evaluation of NT-175, an autologous T cell product engineered to express an HLA-A*02:01-restricted TCR targeting TP53 R175H and resistant to TGF-b inhibition.(2024)1 cited